The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Park, Cheong ^a   Heo, Hyeok ^a   Jeon, Yong ^a   Choi, Ji ^a   Jo, A Ra ^a   Kim, Won ^a   Kwon, Jeong ^b   Hong, Joon ^a   Han, Seok ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Apoptosis; Cytochrome c; Histone deacetylase (HDAC) inhibitor; HNHA; Renal cell carcinoma (RCC)

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 7; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYTOCHROME C; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; I KAPPA B; N HYDROXY 7 (2 NAPHTHYLTHIO)HEPTANOMIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; CASPASE; HISTONE; HYDROXAMIC ACID; N-HYDROXY-7-(2-NAPHTHYLTHIO)HEPTANAMIDE; NAPHTHALENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL NUCLEUS; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; G0 G1 CELL CYCLE ARREST; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MITOCHONDRION; MOUSE; MTS ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TRANSPORT; RENAL CELL CARCINOMA CELL LINE; UPREGULATION; WESTERN BLOTTING; ACETYLATION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CARCINOMA, RENAL CELL; CELL FRACTIONATION; DRUG EFFECTS; ENZYMOLOGY; KIDNEY NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE; TUNEL ASSAY;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CASPASES; CELL FRACTIONATION; CYTOCHROMES C; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; I-KAPPA B PROTEINS; IN SITU NICK-END LABELING; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; NAPHTHALENES; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 84924172363     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-014-1003-1     Document Type: Article

References (34)

1. Garnis C, Buys TP, Lam WL. Genetic alteration and gene expression modulation during cancer progression. Mol Cancer. 2004;22:3-9.
2. Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81(4):303-11.
3. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12-27.
4. Füllgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene. 2011;3:3391-403.
5. Waldmann T, Schneider R. Targeting histone modifications-epigenetics in cancer. Curr Opin Cell Biol. 2013;25:184-9.
6. Johnson C, Warmoes MO, Shen X, Locasale JW. Epigenetics and cancer metabolism. Cancer Lett. 2015;356:309-14.
7. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9:139-48.
8. Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98:604-10.
9. Weichert W, Röske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14:1669-77.
10. Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT, Kuo MY. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 2009;45:610-4.
11. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat. 2005;94:11-6.
12. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769-84.
13. Molina AM, Motzer RJ, Heng DY. Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Semin Oncol. 2013;40:436-43.
14. Mattei J, da Silva RD, Sehrt D, Molina WR, Kim FJ. Targeted therapy in metastatic renal carcinoma. Cancer Lett. 2014;343:156-60.
15. Ramakrishnan S, Pili R. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer J. 2013;19:333-40.
16. Fritzsche FR, Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer. 2008;8:381.
17. Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol. 2008;180:1131-6.
18. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T. Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells. Urology. 2010;76:764. e7-13.
19. Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC, Chung HC, et al. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun. 2007;356:233-8.
20. Park KC, Kim SW, Park JH, Song EH, Yang JW, Chung HJ, et al. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo. Cancer Sci. 2011;102:343-50.
21. Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR Jr ZSG, Modesitt SC. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol Oncol. 2007;104:596-601.
22. Hebbel RP, Vercellotti GM, Pace BS, Solovey AN, Kollander R, Abanonu CF, et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood. 2010;115:2483-90.
23. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277-85.
24. Su D, Stamatakis L, Singer EA, Srinivasan R. Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol. 2014;26:321-7.
25. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463:360-3.
26. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifi es frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539-42.
27. Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol. 2012;6:579-89.
28. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194-202.
29. Brown R, Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol Med. 2002;8:S43-8.
30. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med. 2009;13:2376-85.
31. Tavares TS, Nanus D, Yang XJ, Gudas LJ. Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008;7:1607-18.
32. Mahalingam D, Medina EC, Esquivel 2nd JA, Espitia CM, Smith S, Oberheu K, et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res. 2010;16:141-53.
33. George S, Beeram M, Ricart AD, Mita AC, Brenner AJ, Ketchum N, Egorin MJ, Tolcher AW, Zwiebel JA, Sarantopoulos J. A phase II pharmacokinetic and biologic correlative study of vorinostat (suberoylanilide hydroxamic acid or SAHA) in advanced renal cell carcinoma (RCC) patients (pts). ASCO Genitourinary Cancers Symposium 2010. abstract 374
34. Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 2011;29:451-5.